Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Cross-reactivity00:42

Cross-reactivity

32.7K
Overview
32.7K
Vaccinations01:51

Vaccinations

50.9K
Overview
50.9K
Cancer Vaccines01:30

Cancer Vaccines

870
Cancer treatment vaccines are a rapidly evolving field that offers a promising approach to immunotherapy. Unlike traditional vaccines that prevent diseases, cancer treatment vaccines are designed to treat existing cancers by stimulating the immune system to recognize and attack cancer cells.
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
870
Immunological Memory01:23

Immunological Memory

14.7K
Immunological memory, a pivotal pillar of the adaptive immune system, is responsible for the body's ability to remember and respond more swiftly and effectively to previously encountered pathogens. This remarkable feature is what makes vaccines so effective in preventing diseases.
What is Immunological Memory?
Immunological memory is an integral function of the immune system that allows it to recognize and react more rapidly and effectively to pathogens previously encountered. This feature...
14.7K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Monocyte-derived macrophages drive neurological tissue damage through mitochondrial reactive oxygen species.

Science immunology·2026
Same author

Triggering multiple sclerosis: infection with Epstein-Barr virus activates multiple pre-existing autoreactive B and T cells.

Signal transduction and targeted therapy·2026
Same author

LANA-specific CD4<sup>+</sup> effector T cells accumulate at the site of KSHV infection in humanized mice.

Nature communications·2025
Same author

Humanized Mouse Models of Epstein Barr Virus Infection.

Current protocols·2025
Same author

Chronic antigen stimulation in melanoma induces T cell exhaustion and limits efficacy of T cell bispecific therapies.

Oncoimmunology·2025
Same author

EBV induces CNS homing of B cells attracting inflammatory T cells.

Nature·2025

Related Experiment Video

Updated: Dec 22, 2025

Isolation and Quantification of Epstein-Barr Virus from the P3HR1 Cell Line
09:14

Isolation and Quantification of Epstein-Barr Virus from the P3HR1 Cell Line

Published on: September 28, 2022

4.4K

Vaccination against the Epstein-Barr virus.

Julia Rühl1, Carol S Leung2, Christian Münz3

  • 1Viral Immunobiology, Institute of Experimental Immunology, University of Zürich, Winterthurerstrasse 190, CH-8057, Zürich, Switzerland.

Cellular and Molecular Life Sciences : CMLS
|May 6, 2020
PubMed
Summary

Developing an Epstein-Barr virus (EBV) vaccine is nearing reality, exploring various approaches like viral vectors and glycoprotein formulations. The goal is to mimic natural immune control to prevent EBV-associated diseases.

Keywords:
CarcinomaCytotoxic lymphocytesGlycoprotein multimersInfectious mononucleosisLymphomaNeutralizing antibodiesProphylacticRecombinant viral vectorsTherapeuticVirus-like particles

More Related Videos

Generation of Multivirus-specific T Cells to Prevent/treat Viral Infections after Allogeneic Hematopoietic Stem Cell Transplant
08:52

Generation of Multivirus-specific T Cells to Prevent/treat Viral Infections after Allogeneic Hematopoietic Stem Cell Transplant

Published on: May 27, 2011

17.6K
An Efficient and Simple Method to Establish NK and T Cell Lines from Patients with Chronic Active Epstein-Barr Virus Infection
09:43

An Efficient and Simple Method to Establish NK and T Cell Lines from Patients with Chronic Active Epstein-Barr Virus Infection

Published on: March 30, 2018

9.6K

Related Experiment Videos

Last Updated: Dec 22, 2025

Isolation and Quantification of Epstein-Barr Virus from the P3HR1 Cell Line
09:14

Isolation and Quantification of Epstein-Barr Virus from the P3HR1 Cell Line

Published on: September 28, 2022

4.4K
Generation of Multivirus-specific T Cells to Prevent/treat Viral Infections after Allogeneic Hematopoietic Stem Cell Transplant
08:52

Generation of Multivirus-specific T Cells to Prevent/treat Viral Infections after Allogeneic Hematopoietic Stem Cell Transplant

Published on: May 27, 2011

17.6K
An Efficient and Simple Method to Establish NK and T Cell Lines from Patients with Chronic Active Epstein-Barr Virus Infection
09:43

An Efficient and Simple Method to Establish NK and T Cell Lines from Patients with Chronic Active Epstein-Barr Virus Infection

Published on: March 30, 2018

9.6K

Area of Science:

  • Virology
  • Immunology
  • Vaccinology

Background:

  • Epstein-Barr virus (EBV) is the first identified human tumor virus and the only known human pathogen capable of in vitro cell transformation.
  • Decades of research have led to the development of potential EBV vaccines.

Purpose of the Study:

  • To review current strategies and candidates for an EBV vaccine.
  • To discuss the potential of immunotherapies targeting EBV.

Main Methods:

  • Review of recombinant viral vectors and heterologous prime-boost vaccinations.
  • Exploration of EBV-derived virus-like particles and glycoprotein formulations.
  • Discussion of cell-mediated immunity and antibody-mediated protection.

Main Results:

  • Multiple vaccine candidates are under investigation, reflecting EBV's complex lifecycle.
  • Antibodies may prevent symptomatic primary infection, while cell-mediated immunity protects healthy carriers.
  • Adoptive T cell transfer shows promise for treating EBV-associated malignancies.

Conclusions:

  • The efficacy of EBV vaccine candidates will be determined through human trials.
  • Immunotherapies, including vaccination, can target this oncogenic gamma-herpesvirus.
  • Vaccination strategies should aim to replicate the immune control observed in healthy EBV carriers.